Zymogenetics, Inc.

Alpine Immune Sciences, Inc.

University of Washington

Stacey R Dillon

Jane A Gross

Cindy A Sprecher

Julia E Novak

Angela K Hammond

Scott R Presnell

Donald C Foster

Richard D Holly

Andrew J Nelson

Janet V Johnston

Joseph Leon Kuijper

Mark W Rixon

Wayne R Kindsvogel

Wenfeng Xu

Anthony W Siadak

Yasmin A Chandrasekher

Margaret Dow Moore

Joyce M Lehner

Francis J Grant

Pallavur V Sivakumar

Maria M Dasovich

Stephen R Jaspers

Theodore E Whitmore

Eugene C Yi

Cecile Krejsa

Frederick J Ramsdell

Daniel William Demonte

Lawrence Evans

Stanford L Peng

Zhi Chen

Steven D Hughes

Keith B Elkon

Cecile M Krejsa

Paul O Sheppard

Zeren Gao

Brian A Fox

James L Holloway

Pallavar V Sivakumar

Brandon J Harder

Julie E Novak

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunomodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

April and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs.

Levels of BCMA protein expression on B cells and use in methods of treating systemic lupus erythematosus

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

Methods of producing a zcytor17 heterodimeric cytokine receptor

ZCYTOR17 heterodimeric cytokine receptor

The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with HT antagonists, either singly or in combination with other immune suppressive drugs.

Levels of BLyS/APRIL heterotrimers in serum and use in diagnostic methods

The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.

Anti-IL-20 antibodies and binding partners and methods of using in inflammation

ZCYTOR17 heterodimeric cytokine receptor polynucleotides

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.

Methods of producing anti-IL-22RA antibodies

Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.

Cytokine zalpha11 ligand

Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21  antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, Tcells or T17 cells.

Methods of treatment using anti-human IL-21 monoclonal antibodies

Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Anti-human IL-21 monoclonal antibodies

Growing community of inventors

Seattle, WA, United States of America

Stacey R Dillon